Globus Medical's consensus analyst price target has seen a modest decline, moving from $80.30 to $78.18, following a slight uptick in the discount rate. These adjustments reflect a shifting narrative ...

The third-quarter 2025 earnings season is underway, with several healthcare companies already reporting their results. Early ...

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized ...

Globus Medical stock is currently trading approximately 33% below its 1-year high and is also trading at a PS multiple that ...

Across the recent three months, 8 analysts have shared their insights on Globus Medical (NYSE:GMED), expressing a variety of opinions spanning from bullish to bearish. The table below provides a ...

Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call ...

Across the recent three months, 11 analysts have shared their insights on Globus Medical (NYSE:GMED), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

Globus Medical reports quarterly earnings of 72 cents per share which beat the analyst consensus estimate of 57 cents by 26.32%. Quarterly sales come in at $606.67 million which beat the analyst ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Additionally, its string of product launches is highly promising to drive growth in ...

Globus Medical launched the Anthem Elbow Fracture System, a plating system designed to help surgeons manage a wide range of elbow fractures with simplified workflow and flexible fixation options.